Your browser doesn't support javascript.
loading
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma.
Strati, Paolo; Jallouk, Andrew; Deng, Qing; Li, Xubin; Feng, Lei; Sun, Ryan; Adkins, Sherry; Johncy, Swapna; Cain, Taylor; Steiner, Raphael E; Ahmed, Sairah; Chihara, Dai; Fayad, Luis E; Iyer, Swaminathan P; Horowitz, Sandra; Nastoupil, Loretta J; Nair, Ranjit; Hassan, Ahmed; Daoud, Taher E; Hawkins, Misha; Rodriguez, Maria A; Shpall, Elizabeth J; Ramdial, Jeremy L; Kebriaei, Partow; Hong, David S; Westin, Jason R; Neelapu, Sattva S; Green, Michael R.
Afiliação
  • Strati P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Jallouk A; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Deng Q; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Li X; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Sun R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Adkins S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Johncy S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Cain T; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Steiner RE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ahmed S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Chihara D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Iyer SP; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Horowitz S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Nair R; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Hassan A; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Daoud TE; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Hawkins M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Rodriguez MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Shpall EJ; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ramdial JL; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Kebriaei P; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Westin JR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Green MR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Blood Adv ; 7(21): 6785-6789, 2023 11 14.
Article em En | MEDLINE | ID: mdl-37389847
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Proteína Antagonista do Receptor de Interleucina 1 Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Proteína Antagonista do Receptor de Interleucina 1 Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article